Advertisement
News
Advertisement

Reportlinker Adds Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally

Tue, 01/11/2011 - 6:34am
Bio-Medicine.Org

NEW YORK, Jan. 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Germany Pharmaceutical Market Overview – New pricing rules set to negatively impact drug sales both domestically and internationally

http://www.reportlinker.com/p0360217/Germany-Pharmaceutical-Market-Overview-–-New-pricing-rules-set-to-negatively-impact-drug-sales-both-domestically-and-internationally.html

IntroductionThe German prescription pharmaceutical market was valued at $38.3 bn in 2009, with an annual growth rate of 4.4% between 2008 and 2009. However, future market growth will be hampered by the newly introduced price negotiation requirements in addition to raised rebates for patent protected drugs, with an impact on other countries that use Germany as a reference market.

Features and benefits

* Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property in Germany* Assesses the size of the Germany pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies* Examines the Germany generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion* Quantifies the R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis

HighlightsLow birth rate in Germany has led to a demog

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading